“We are excited to announce a strategic collaboration with and investment in Anjo.ai, a company whose goal is to bring real-time anaphylaxis detection to the tens of millions at risk of sudden death from anaphylaxis, a life-threatening reaction to food, insect venom, medicine, or latex.”

Stephen Benford, former VP of Finance & CFO of Global Operations at Revvity, a global life sciences company, will be joining Anjo as Chief Financial Officer and will join the company’s Board of Directors. “We are honored to carry Abbie’s legacy forward and are stronger with Stephen on our team to carry out our mission: Save Lives, and improve quality of life for tens of millions at risk of anaphylaxis”, said Tal Golan, CEO of Anjo.ai.

“Abbie died because of a gap in the detection phase of anaphylaxis. We have been working since 2014 to close this gap with technology to detect an anaphylactic reaction, funding research at the Wyss Institute at Harvard University and Boston Children’s Hospital. The Foundation is thrilled to collaborate with Anjo.ai, and I am excited to join the Anjo team. Our goals are directly aligned: provide real-time anaphylaxis detection to the tens of millions of people at risk of sudden death from anaphylaxis; essentially, develop a device that might have saved Abbie’s life.” said Benford, Abbie’s father and Co-Founder & Executive Director of The KeepSmilin4Abbie Foundation®.

From the start our goal for the Foundation has been to support scientists’ and engineers’ efforts to identify the biomarkers of anaphylaxis and create the capability to monitor and alert people at risk of sudden death from anaphylaxis. This collaboration and The Foundation’s financial support is directly aligned with this goal and accelerates the path to achieving it.

To learn more visit the Foundation’s website KeepSmilin4Abbie.org or the company’s website Anjo.ai.”